More generally, this data suggests that DC-based strategies which prime CD8+ T cell responses in an immunoproteasome-rich environment may run the risk of selecting CD8+ T cell populations which are unable to recognize target cells, in settings where a virus (or even tumor) has modified its immunoproteasome cargo. This evidence concerns the gene CD8A and neoplasm.